With an analyst consensus upside of 79.4%, Alumis Inc. (NASDAQ:ALMS) ranks among the under-the-radar stocks with massive upside for 2026. Alumis Inc. (NASDAQ:ALMS) drew three analyst price target ...
Alumis Inc. (NASDAQ:ALMS) is one of the 11 Best New Penny Stocks to Buy Right Now. On May 21, Alumis Inc. (NASDAQ:ALMS) reported that it has completed its merger with ACELYRIN, Inc. As part of this ...
Opinion
11dOpinion
Is Alumis (ALMS) Trading Short-Term Revenue for a Leaner, More Focused Business Model?
Alumis Inc. recently reported first-quarter 2026 results, with revenue of US$1.74 million versus US$17.39 million a year earlier and a net loss of US$93.05 million compared with US$98.96 million ...
1mon
Alumis Inc.
View Alumis Inc. ALMS stock quote prices, financial information, real-time forecasts, and company news from CNN.
Alumis Inc. ( (ALMS)) has shared an announcement. On January 2, 2026, Alumis Inc. and its subsidiary Acelyrin issued a Notice of Material Breach and claim for indemnification to Climb Bio after Climb ...
Alumis (ALMS) shares climbed nearly 150% on Tuesday after the autoimmune disease drug developer said its lead candidate, envudeucitinib, reached the main goals in two Phase 3 trials for a skin ...
Alumis announced strong phase three trial results for its plaque psoriasis drug Biotech stock Alumis Inc (NASDAQ:ALMS) is skyrocketing today, up 107.9% at $17.28 at last glance, after the Johnson & ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results